ArticleLife science alliance2020

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.

Linda K Rushworth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.